GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...
The complex shape of respiratory syncytial virus (RSV) is one hurdle limiting the development of treatments for an infection ...
The 2024-25 respiratory season is underway and for the first time, New Brunswick will offer some seniors immunization against ...
The complex shape of respiratory syncytial virus is one hurdle limiting the development of treatments for an infection that leads to hospitalization or worse for hundreds of thousands of people in the ...
Respiratory syncytial virus, or RSV, season is just a few months away, but new vaccine options have already arrived for ...
The complex shape of respiratory syncytial virus is one hurdle limiting the development of treatments for an infection that ...
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy (MAL24086007ARZ) has been approved in Malaysia for ...
Enanta Pharmaceuticals' EDP-323 shows promising Phase 2a trial results, significantly reducing RSV viral load and symptoms ...
This fall and winter, Ontario, Quebec and Nunavut will offer the newer monoclonal antibody nirsevimab — approved by Health ...
Yesterday during its annual news conference, the National Foundation for Infectious Diseases (NFID) said less than 1 in 5 ...
Respiratory syncytial virus, or RSV, season is just a few months away, but new vaccine options have already arrived for ...
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that the Arexvy vaccine (MAL24086007ARZ) has been approved in Malaysia for respiratory syncytial virus (RSV). RSV is a common respiratory ...